On January 21, Vyant Bio Inc. (VYNT) stock fell by a further 14.17% in the after-market session.
In the regular trading session, the stock lost 6.25% at its close of $1.20. This downtrend continued into the after hours, as VYNT plunged further down to $1.03. Hence, the stock has gone well below its 52-week low of $1.1950.
The advanced biotechnology drug discovery company, Vyant Bio Inc. was founded in 1999. Currently, its 28.99 million outstanding shares trade at a market capitalization of $34.79 million. Furthermore, VYNT stock presently stands at a year-to-date loss of 11.11% while it lost 71.50% last year.
Why VYNT Declined?
As of recently, there has been no official news, new SEC filing, or an upcoming event in the company’s timeline. Despite this, the VYNT stock has been going up and down, probably due to some social media chatter. While the stock has mainly been in a downtrend, it has also seen occasional slight additions as well.
On Friday, the stock fell down to a low of $1.20 and closed the session at the same. VYNT stooped well below its 52-week low of $1.1950 in the after-hours as it reached $1.03. Given the new low, the stock might present a good buying opportunity and possibly recover in the next session. But then again, it all depends on how the investors see this low, as the stock has been all but going down.
Recent Participations
Recently, the company participated in the H.C. Wainwright Bioconnect Conference which was held from January 10-13, 2022. Moreover, VYNT’s CEO, Jay Roberts, and Chief Scientific Officer, Robert Fremeau discussed key highlights of the company from 2021. In addition, they also provided a business and strategic outlook for 2022.
Previously, the company also participated in The Benchmark Company Discovery One-on-One Investor Conference on December 02, 2021.
Before that, the company had presented at the Q4 Investor Summit Micro & Small-Cap Conference in November 2021.
VYNT’s Q3 2021 Financial Analysis
On November 11, the company disclosed its financial data for the third quarter of 2021.
In the third quarter of 2021, the company had total revenues of $1.5 million.
In addition, the research & development, and selling, general & administrative expenses were $1.2 million and $3.3 million, respectively.
Further, VYNT ended the quarter with cash and cash equivalents of $23.3 million on September 30, 2021.
